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ABSTRACT
Type 2 diabetes (T2D) is associated with reduced gut microbiome diversity, although the cause is 
unclear. Metabolites generated by gut microbes also appear to be causative factors in T2D. We 
therefore searched for serum metabolites predictive of gut microbiome diversity in 1018 females 
from TwinsUK with concurrent metabolomic profiling and microbiome composition. We generated 
a Microbial Metabolites Diversity (MMD) score of six circulating metabolites that explained over 
18% of the variance in microbiome alpha diversity. Moreover, the MMD score was associated with 
a significantly lower odds of prevalent (OR[95%CI] = 0.22[0.07;0.70], P = .01) and incident T2D (HR 
[95%CI] = 0.31[0.11,0.90], P = .03). We replicated our results in 1522 individuals from the ARIC study 
(prevalent T2D: OR[95%CI] = 0.79[0.64,0.96], P = .02, incident T2D: HR[95%CI] = 0.87[0.79,0.95], 
P = .003). The MMD score mediated 28%[15%,94%] of the total effect of gut microbiome on T2D 
after adjusting for confounders. Metabolites predicting higher microbiome diversity included 
3-phenylpropionate(hydrocinnamate), indolepropionate, cinnamoylglycine and 5-alpha-pregnan 
-3beta,20 alpha-diol monosulfate(2) of which indolepropionate and phenylpropionate have already 
been linked to lower incidence of T2D. Metabolites correlating with lower microbial diversity 
included glutarate and imidazole propionate, of which the latter has been implicated in insulin 
resistance. Our results suggest that the effect of gut microbiome diversity on T2D is largely 
mediated by microbial metabolites, which might be modifiable by diet.
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Introduction
Type 2 diabetes (T2D) is a major public health 
burden with a 10-fold increase in T2D rates globally 
between 1980 (30 million) and 2010 (300 million).1 
Accumulating evidence indicates that bacteria in 
the human gut play a vital role in the pathophysiol-
ogy of T2D and related traits,2–7 with higher gut 
microbiome alpha diversity having a beneficial 
effect.
Gut microbiome composition is regulated jointly 
by the host genome, the colonic milieu and diet.6 
During digestion, gut microbes coproduce a wide 
range of metabolites such as short chain fatty acids 
(SCFAs),8 lipopolysaccharide (LPS),9 imidazole 
propionate,10 among others, that are essential for 
regulating multiple host-microbiome pathways.11 
Previous studies in animals and humans have iden-
tified a gut microbiome signature of T2D.6,7 
Individuals with T2D have lower gut microbiome 
alpha diversity compared with healthy controls and 
they also show impaired SCFA butyrate 
production,12 modifications in incretin secretion, 
reducing intestinal permeability leading to meta-
bolic endotoxemia (increased LPS in blood)13,14 
that is linked to increasing metabolic inflammation 
and insulin resistance induced by high-fat diet.15
In addition, a number of studies have shown that 
microbial metabolites, other than SCFAs, are linked 
to the development of T2D,16 suggesting that part 
of the benefit of having a diverse gut microbiome is 
related to an improvement of the metabolic cross- 
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talk occurring between the gut microbes and their 
host.17
A recent study has found that 40 metabolites, 
including 13 of them of microbial origin18 can 
predict 45% of the inter-individual variation in 
alpha diversity. However, the study did not focus 
on the specific relevance of bacterial metabolites to 
T2D, but primarily on the usefulness of human and 
bacterial metabolites as biomarkers predictive of 
diversity.
Here we identify serum metabolites reflective of 
gut microbiome function that can mediate the 
effect of gut microbiome composition on T2D and 
related metabolic traits in a large UK cohort. We 
replicate our results in an independent US sample.
Results
The descriptive characteristics of the study popula-
tions are presented in Table 1. We included 1018 
middle-age females from TwinsUK with 16 s gut 
microbiome data and concurrent fasting serum 
metabolomics. The replication cohort consisted of 
1522 male and female participants from the ARIC 
study of European ancestry.
We randomly divided the TwinsUK study sam-
ple into two independent sets: a discovery set of 409 
individuals and a test set of 609 individuals. Six 
metabolites were associated with Shannon diversity 
after adjusting for age, BMI, family relatedness (as 
random effect) and multiple testing (using 
Bonferroni correction P < 1.68x10−4 = 0.1/596 
metabolites) in the discovery set (Table S1). Of 
these, there were four amino acid derivatives, one 
steroid and one xenobiotic. We then created 
a microbial metabolite diversity (MMD) score in 
females from TwinsUK to assess the combined 
effects of all metabolic traits identified, by including 
the six metabolites into a linear regression. We 
found that the MMD score explains 27% of the 
variance in Shannon Diversity (Figure 1) and the 
variance inflation factor (VIF) between the selected 
feature was low (VIF = 1.38) suggesting low 
collinearity.19 
MMD score ¼   0:0476306þ 0:1746576
� 3   phenylpropionate hydrocinnamateð Þð ÞÞ
  0:0867652� imidazolepropionateð Þ
þ 0:1461903� cinnamoylglycineð ÞÞ
þ 0:1674953�
5alphapregnan 3beta;
20alpha diolmonosulfate 2ð Þ
� �
  0:145269� glutarate pentanedioateð Þð Þ
þ 0:0683178� ðindolepropionateÞ
We then replicated the Shannon-metabolite asso-
ciation in 609 independent individuals from the test 
set. All metabolites were significantly associated 
with Shannon diversity after adjusting for covari-
ates and multiple testing in the test set (Figure 1). 
We also tested the predictive value of the MMD 
score in the test set and we found that it explained 
18.68% of the variance in Shannon diversity (Beta 
(SE) = 1(0.09), P = 3.32x10−26). We combined the 
results of the discovery and test set using Fixed 
Effect Meta-Analysis (Figure 1).
To further investigate the predictive value of the 
MMD score, we tested it for association with the 
other alpha diversity indexes in the overall cohort. 
As shown in Figure 2 and Table S1, the MMD score 
was significantly associated with the observed num-
ber of OTUs (Beta (SE) = 0.99(0.06), P = 2.84x10−55; 
r = 0.42, R2 = 0.19), Simpson Index (0.65 (0.08), 
P = 5.97x10−16; r = 0.3, R2 = 0.08) and Chao1 Index 
(0.46 (0.07), P = 4.21x10−12; r = 0.2, R2 = 0.04)
We then tested the association between the MMD 
score and T2D and related phenotypes adjusting for 
age and BMI. We find that the MMD score was 
associated with a lower odds of both prevalentT2D 
(OR[95%CI] = 0.22[0.07;0.70],P = .01) and with 
lower risk of incident T2D (HR[95%CI] = 0.31 
[0.11,0.90], P = .03). We repeated the adjusting also 
for baseline fasting glucose and results were consis-
tent. The MMD score was also negatively correlated 
with BMI, visceral fat mass, fasting glucose and 
Table 1. Descriptive characteristics of the study population.
TwinsUK ARIC
N (%) N (%)
N 1018 1522
Females, % 1018 (100%) 827 (54.3%)
T2D prevalent cases, 47 (4.72%) 119 (7.8%)
T2D incident cases 23 467 (34.7%)
Mean (SD) Mean (SD)
Age, yrs 65.19 (7.74) 54.56 (5.74)
BMI, kg/m2 26.19 (4.83) 27.25 (5.01)
Homa2-IR 0.93 (0.67)
Glucose, mmlol/l 4.75 (0.63) 5.84 (1.54)
VFM, (g) 606.77 (290.07)
Indices of microbiome diversity
Shannon Diversity 5.14 (0.7) NA
Observed number of OTUs 89.38 (113.52) NA
Simpson diversity 0.92 (0.06) NA
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HOMA2-IR, as shown in Figure 2 and in Table S1. 
We find that the associations between the MMD 
score and clinical variables were actually stronger 
than those with actual microbiome diversity (Table 
S1). To confirm the relevance of the metabolites 
identified we replicated the metabolite score associa-
tion with both prevalent and incident T2D in 1522 
individuals of European Ancestry from the ARIC 
cohort. As shown in Figure 3, we find that the 
MMD score was significantly associated with 
a lower risk of prevalent and incident T2D both in 
ARIC (Prevalent T2D: OR[95%CI] = 0.79[0.64,0.96], 
P = .02; Incident T2D: HR[95%CI] = 0.87[0.79,0.95], 
P = .003) and in the meta-analysis which pooled 
estimates from TwinsUK and ARIC (Prevalent 
T2D: OR[95%CI] = 0.75[0.62,0.92], Fixed Effect 
P = .006, Han & Eskin20 Random-Effect P = .006; 
Incident T2D: HR[95%CI] = 0.86[0.78,0.95], 
P = .002, Han & Eskin Random-Effect P = .004).
We further replicated the cross-sectional associa-
tion of the MMD score with BMI (Beta (SE) = −0.59 
(0.13), P = 5.03x10−6)). Considering the gender 
difference in microbiota and metabolism, we 
rerun the analysis in ARIC stratifying by gender 
and we find that the MMD score performance is 
not always better in females than males though the 
directionality is always consistent (Table S2).
To test our hypothesis that the association 
between diversity and T2D is due to the metabolites 
produced by the microbes we then retested for an 
association between T2D with the Shannon diver-
sity index after adjusting for metabolites. We found 
there was no significant association between T2D 
and alpha diversity when adjusting for the MMD 
Figure 1. Metabolites trait significantly associated with gut microbiome alpha diversity (Shannon Index) in the discovery and test set of 
the TwinsUK cohort and in the overall cohort (using inverse variance fixed effect meta-analysis). Analyses adjusted by age, sex, body 
mass index, family relatedness, and multiple testing. CI indicates confidence interval.
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Figure 2. Microbial traits (MMD score, alpha diversity, microbial metabolites), T2D and related traits. Each cell of the matrix contains the 
correlation coefficient between one microbial trait and a metabolic phenotype score and the corresponding P value. The table is color 
coded by correlation according to the table legend (red for positive and blue for negative correlations). Analyses are adjusted for age and 
BMI. ObsOTUs = number of observed OTUs, BMI = body mass index, VFAT = visceral fat mass, HOMA2IR = insulin resistance, T2D = type 2 
diabetes, MMD = Microbial Metabolites Diversity score, Shannon = Shannon Alpha Diversity Index, Phenylp = 3-phenylpropionate 
(hydrocinnamate), Imidazolep = imidazole propionate, IPA = indolepropionate, Cinnamoylgl = cinnamoylglycine, Alphapregan = 5alpha- 
pregnan-3beta,20alpha-diol monosulfate (2).
Figure 3. MMD score and risk of (a) prevalent and (b) incident T2D in the TwinsUK (TUK) and ARIC cohorts and results from fixed effect 
meta-analyses.
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score (OR[95%CI] = 0.81[0.47, 1.38], P = .437), 
while the MMD score is significantly associated to 
a lower risk of T2D when adjusting for Shannon 
diversity (OR[95%CI] = 0.26[0.07,0.93], P = .038). 
We therefore conducted formal mediation analysis 
to determine the indirect effect of the MMD score 
on the effect between Shannon diversity (high ver-
sus low defined as above or below the median, 
respectively) and T2D. The mediation model, 
which intends to evaluate the strength of the indir-
ect effects, found that the direct relationship 
between microbiome factors and T2D was not sta-
tistically significant (path coefficient = −.026[−0.06; 
0.002]). For indirect effect, the effect of the MMD 
was statistically significant (path coefficient = −0.24 
[−0.87; −0.39]). The VAF score for the MMD was 
0.28[0.15; 0.94].
Discussion
In this study, we identified a panel of circulating 
metabolites reflective of gut microbiome alpha 
diversity metrics, which was associated with T2D, 
obesity, adiposity, and other metabolic traits. We 
found the associations between microbiome diver-
sity and T2D related metabolic traits were stron-
ger with the metabolite surrogate measures than 
with the actual diversity measures. Our mediation 
analysis suggests that 28% of the effect the gut 
microbiome alpha diversity has on T2D is 
mediated by gut microbiota-associated metabo-
lites. Some of these metabolites are produced by 
gut bacteria and absorbed through the gut barrier 
to then reach the bloodstream (3-phenylpropio-
nate, IPA, cinnamoylglycine and imidazole pro-
pionate), suggesting that the associations between 
microbiome diversity and metabolic outcomes are 
simply reflecting the effect of some of these meta-
bolites. A more diverse microbiome contains 
a higher number of metabolic pathways and 
hence is likely to be producing a relatively greater 
number of metabolites that contribute to lower 
inflammation and improved metabolic health, 
such as IPA, cinnamic acid and 3-phenylpropio-
nate. Four of these compounds are the result of 
microbial amino acid metabolism pathways, one 
of them is the result of steroid microbial metabo-
lism and one is a phenolic conjugate of a short 
chain fatty acid.
Importantly, all of the metabolites that we have 
identified as being strongly predictive of micro-
biome diversity can be found in human stool sam-
ples (see, e.g.,21).
A much larger number of metabolites have been 
shown to be predictive of alpha diversity in a recent 
study with a smaller sample size18 using a LASSO 
approach. However, less than 25% of those metabo-
lites are of microbial origin, which for our purposes, 
i.e., to identify metabolites that mediate the effect of 
the gut microbiome on T2D development, risks con-
founding causes and effects by including metabolites 
of purely human origin. In this study, we have 
focused on identifying metabolites of microbial ori-
gin that are individually associated and replicated 
after adjustment for multiple tests making these 
much more likely to be implicated in the causal 
link between gut microbiome diversity and T2D.
Compounds associated with lower microbiome 
alpha diversity
Glutarate is produced by the human body as part of 
the metabolism of tryptophan and lysine. It is pro-
duced via lysine degradation in microorganisms22 and 
the microbiome is now known to be an important 
source of this compound which has been linked to 
cancer and organic acidurias.22 Importantly, glutarate 
has already been reported to correlate with lower 
microbiome richness linked to severe obesity.23
Imidazole propionate is a microbially produced 
histidine-derived metabolite.10 This compound is 
present at higher concentrations in the portal and 
peripheral blood of subjects with type 2 diabetes.10 
Imidazole propionate can worsen glucose tolerance 
when administered to mice and impairs insulin 
signaling at the level of insulin receptor substrate 
through the activation of p38γ MAPK, which pro-
motes p62 phosphorylation and, subsequently, acti-
vation of mTORC1.10 The association with obesity, 
T2D and glucose that we found is therefore not 
surprising and in fact confirms the results seen in 
the Dutch cohorts studied for this compound.10
Compounds associated with higher microbiome 
alpha diversity:
Indolepropionic acid (IPA) is a deamination pro-
duct of tryptophan that can only be produced by 
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gut microbes.24 It regulates gastrointestinal barrier 
function via its interaction with the pregnane 
X receptor (PXR), which is predictive of the onset 
of type 2 diabetes,16 has been shown to be strongly 
correlated with higher gut microbiome diversity 
and its levels in serum are determined primarily 
by gut microbiome composition.25
Among the compounds that intestinal bacteria 
can metabolize there are sterols, bile acids, and 
steroid hormones.26 The metabolites generated by 
gut bacteria action on host steroids, when reab-
sorbed in the intestine back into the circulation, 
produce biological effects.26 The formation of sul-
fated steroids with a 3 alpha-hydroxy-5 alpha is 
normally derived from progesterone and account 
for at least 50% of the metabolism of progesterone 
in late pregnancy.27 Compounds in this class have 
been implicated in the severity of premenstrual 
symptoms.28 This compound however is also pre-
sent in human feces21 and importantly it has been, 
along with IPA, reported to be decreased in the 
plasma of patients with primary dilated 
cardiomyopathy.29 We found that higher serum 
levels of 5-alpha-pregnan-3beta,20 alpha-diol 
monosulfate (2) were positively correlated with 
microbiome diversity and in the context of the 
metabolite score, with lower BMI, VFAT and risk 
of T2D. The negative association with primary 
dilated cardiomyopathy is particularly relevant as 
that study included both men and women with an 
average age of 47 y, suggesting that the microbial 
origin of the metabolite may be the same for both 
genders. Indeed, Wilmanski and colleagues18 
reported that serum concentrations of 5-alpha- 
pregnan-3beta,20 alpha-diol monosulfate (2) were 
slightly higher in men than in women and that this 
steroid is associated with microbiome diversity in 
both males and females.
3-phenylpropionic acid is an organic acid that is 
abundantly found in the products of lactic acid 
bacterial fermentation30 and in honey.31 It is an 
antimicrobial compound with broad-spectrum 
activity against a wide range of Gram-positive bac-
teria, some Gram-negative bacteria and fungi.32 
3-phenylpropionic acid along with phenylacetic 
acid is one of the main phenolic metabolites present 
in human feces. Its levels in feces have been shown 
to be inversely correlated with fecal levels of pro-
pionate and positively correlated with fecal levels of 
acetate. It appears therefore to be directly related to 
SCFA metabolism.33 Given its correlation with 
dietary fiber, it is not surprising that it is associated 
positively with microbiome diversity. The mechan-
ism by which it influences cardiometabolic traits is 
unknown but we hypothesize that its antimicrobial 
properties may result in lower production of lipo-
polysaccharide and that its antioxidant activities 
may contribute to decreased risk of obesity and 
insulin resistance.34
Cinnamic acid is a naturally occurring bioactive 
compound synthesized in plants by the shikimate 
pathway, where phenylalanine and tyrosine are 
two precursor molecules. It is found in plant- 
based foods such as fruits, vegetables, and whole 
grains and several potential benefits of cinnamic 
acid and its derivatives have been demonstrated in 
in vitro and preclinical studies with regards to 
T2D, although there is no clinical evidence.35 
Cinnamoylglycine is a glycine conjugate of cin-
namic acid and it is known to be produced by 
gut microbes because it is abundant in the serum 
of conventional mice but present in minimal con-
centrations in the serum of germfree mice.24 
Cinnomoylglycine has substantially greater urin-
ary clearance than creatinine36 and hence accumu-
lates in plasma under conditions of diminished 
renal function. In our data, we found that the 
association between cinnomoylglycine, diversity 
and clinical traits was not affected when adjusting 
for creatinine. Although its functional effects in 
humans are unknown, urinary excretion levels of 
cinnamoylglycine have been proposed as markers 
of colonization resistance against Clostridium dif-
ficile, i.e., as a marker of a healthy gut microbiome 
that can inhibit the growth of pathogenic 
microorganisms.37
The current study has several strengths. The 
study benefits from a big sample size, the use of 
internal subsets for discovery and retesting, a large 
independent replication cohort and a large number 
of metabolites. Both TwinsUK and ARIC have 
extensive phenotypic data available that allowed 
us to accurately classify subjects according to T2D 
status. Finally, the robustness of our result is high-
lighted by the fact that we confirm many previous 
findings, and the predictive value of our metabolic 
score is successfully validated in an independent 
sample.
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Our study has some limitations. Because 
TwinsUK is a sample representative of the general 
UK population the number of prevalent and inci-
dent cases of T2D in a sample of ~1000 individuals 
is relatively modest (n = 47 and 23, respectively) 
hence the large confidence intervals. Moreover, the 
definitions for T2D are different in the two cohorts. 
In the TwinsUK subjects, glucose concentration 
was only measured in the fasting state, potentially 
underestimating T2D incidence. This and the lack 
of men in the analysis are study limitations that are 
at least in part overcome by the inclusion of the 
ARIC cohort, which includes men and a much 
larger number of individuals with incident and 
prevalent T2D. Also, we were not able to test for 
the association between the MMD score and 
Shannon diversity and the mediation analysis 
results in ARIC as data on 16 s gut microbiome 
data was not available.
In conclusion, in this study, we find that a set of 
six microbially derived or microbially modified 
metabolites in serum was predictive of gut micro-
biome diversity and of T2D risk in two indepen-
dent populations, and we report that the effect of 
gut microbiome diversity on risk of T2D is in part 
mediated by these metabolites. Clinical studies 
should investigate the pathways identified and 
determine whether modifying these compounds 




We included a random subset of 1018 females from 
TwinsUK representative of the general middle age 
female UK population38 with concurrent fasting 
serum metabolomic profiling (592 metabolites) 
and fecal 16 S sequencing (measuring microbiome 
composition) along with diabetic and metabolic 
information. T2D prevalent cases were defined as 
individuals with fasting glucose≥7 mmol/l or with 
a physician’s letter confirming diagnosis or use of 
medication for diabetes. Visceral fat (VF), BMI, 
obesity and Homa2-IR were measured as pre-
viously described.25 Incident T2D cases were 
defined with the same criteria but having developed 
T2D at follow-up (mean (SD) = 8.16 (1.3) y).
The study was approved by NRES Committee 
London–Westminster, and all twins provided 
informed written consent.
The replication cohort consisted of 1522 European 
American (T2D incident cases 467, T2D prevalent 
cases 119) from the Atherosclerosis Risk in 
Communities (ARIC) study with fasting metabolo-
mic profiles.39 In the ARIC study, prevalent diabetes 
at baseline was defined as fasting glucose ≥7.0 mmol/ 
l, non-fasting glucose ≥11.1 mmol/l, self-reported 
diagnosis of diabetes by a physician or use of medica-
tion for diabetes within the previous 2 weeks. The 
incidence of diabetes was ascertained from visit 1 
(1987–1989) until December 31, 2015. Incident dia-
betes was defined as elevated glucose (fasting glucose 
≥7.0 mmol/l or non-fasting glucose ≥11.1 mmol/l) at 
any of three triennial follow-up visits and visit 5 
(2010–2013), self-report of a diabetes diagnosis by 
a physician at a study visit or annual follow-up tele-
phone interview, or self-report of diabetes medica-
tion use during a study visit or annual follow-up 
telephone interview.40 The incidence of diabetes 
was ascertained from visit 1 until December 31, 2015.
Note, the accumulative T2D incidence per year is 
0.4%[0.16%; 1.02%] in the subset of TwinsUK indivi-
duals included in this study, 1.1%[0.62%; 1.96%] in the 
participants from ARIC included here. This compares 
to 0.67% [0.53%;085%] in US individuals according to 
the National Diabetes Statistics Report.41
Metabolomics profiling
Metabolomics profiling was conducted using ultra- 
high-performance liquid chromatography-tandem 
mass-spectrometry by the metabolomics provider 
Metabolon Inc. (Morrisville, USA) on fasting 
serum samples from participants in the TwinsUK 
study and ARIC, as described previously,39,42 for 
details see Supplementary Text. The metabolomic 
dataset measured by Metabolon includes 592 
known metabolites containing the following broad 
categories – amino-acids, peptides, carbohydrates, 
energy intermediates, lipids, nucleotides, cofactors 
and vitamins, and xenobiotics. These include meta-
bolites of established microbial origin.43 We inverse 
normalized circulating metabolite levels as the 
metabolite concentrations were not normally dis-




Gut microbiome composition was determined by 
16 S rRNA gene sequencing carried out as pre-
viously described.44 Briefly, the V4 region of the 
16 S rRNA gene was amplified and sequenced on 
Illumina MiSeq. Reads were then summarized to 
operational taxonomic units (OTUs) Quality con-
trol was carried out on a per sample basis, discard-
ing paired-ends with an overlap of less than 200nt 
and removing chimeric sequences using de novo 
chimera detection in USEARCH.45 De novo OTU 
clustering was then carried across all reads using 
Sumaclust within QIIME 1.9.0, grouping reads with 
a 97% identity threshold.46,47 OTU counts were 
converted to log transformed relative abundances, 
with zero counts handled by the addition of an 
arbitrary value (10–6). In order to calculate alpha 
diversity, the complete OTU count table was rare-
fied to 10,000 sequences per sample 50 times. Alpha 
diversity metrics were calculated for each sample in 
each of the rarefied tables and final diversity mea-
sures taken as the mean score across all 50. Alpha 
diversities were quantified as observed OTU counts 
and Shannon and Simpson diversity indices, com-
monly used to characterize species diversity in 
a community. They both account for abundance 
and evenness of the species present. Alpha diversity 
indexes were standardized to have mean 0 and 
SD 1.
Statistical analysis
Statistical analysis was carried out using Stata ver-
sion 12 and R version 3.6.0.
In the TwinsUK cohort, we randomly divided 
study subjects into two independent subsets: 
a discovery set including 409 individuals (1/3 of the 
sample) and a test set of 609 individuals (2/3) of the 
sample. In the discovery set, association analyses 
between gut microbiome composition and metabo-
lites were performed using random intercept linear 
regression adjusting for age, body mass index, family 
relatedness and multiple testing using Bonferroni 
correction (P < 1.68x10−4 = 0.1/596 metabolites). 
We linearly combined the metabolites significantly 
associated with Shannon Diversity to create 
a Microbial Metabolites Diversity (MMD) score. 
We validated the score in 609 females from 
TwinsUK. Results from the Discovery and Test set 
were combined using inverse variance fixed effect 
meta-analysis as implemented in the R package 
meta. We further tested the predictive value of the 
MMD score by testing its association with T2D and 
related traits (obesity, BMI, visceral fat, fasting glu-
cose, insulin resistance) and with other measures of 
diversity in the overall cohort. We replicated the 
results in 1522 male and female participants of 
European ancestry from ARIC. In the ARIC study, 
we applied linear regression to test the association 
between the MMD score and BMI adjusting for age, 
sex and center. We next applied logistic and Cox 
regressions to test the association between the 
MMD score and prevalent and incident T2D adjust-
ing age, sex, center and BMI. Prevalent T2D cases 
were excluded from the incident T2D analysis. We 
did not observe violation on the proportional 
hazards assumption for MMD score.
Results were combined using inverse variance 
fixed effect meta-analysis as implemented in the 
R package meta and, since the sex distributions of 
the two cohorts are different, also using Han & 
Eskin20 random-effect meta-analysis as implemen-
ted in the software metasoft.
Finally, we employed mediation analysis as 
implemented in the STATA package MedEff to 
test the mediation effects of microbial metabolites 
(indirect effect) on the total effect of microbiome 
factors (Shannon Index) on T2D adjusting for age 
and BMI. We constructed a mediation model to 
quantify both the direct effect of microbiome 
factors on T2D and the indirect (mediated) effects 
mentioned above. The model goodness of fit was 
assessed by standardized path coefficient and 
effect size (f2)48–50 yield using the lower and 
upper bound of the 95% confidence interval. 
The variance accounted for (VAF) score, which 
represents the ratio of indirect-to-total effect and 
determines the proportion of the variance 
explained by the mediation process, was further 
used to determine the significance of mediation 
effect.51
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